N/A N=84 Endotracheal Tube Versus Laryngeal Mask Airway for Esophagogastroduodenoscopy
Airway Morbidity
Primary: Endoscopist Satisfaction — 1.0; 1.1 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Pancreatic Neuroendocrine Tumors (pNET)
Primary: Stage 1 - Progression Free Survival (PFS) Rate Analysis at 16 Weeks as Per Local Radiology Review — 51.6 Percentage of participants
Phase 1 N=74 Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers
Healthy
Primary: AUC — 150607; 152208; 504584; 544818 (pg/ml)*hour
N/A N=563 An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer
Breast Cancer, Colorectal Cancer, Gastric Cancer
Primary: Number of Participants With Routine Clinical Use of Capecitabine as Per the Line of Treatment — 220; 176; 89; 78 Participants
Phase 3 N=163 LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Anemia
Primary: Percentage of Participants Maintaining Their Mean Hb Concentration Within ±1.0 Gram/Deciliter of Their Reference Hb and Between 10.5 and 12.5 Gram/Deciliter — 43.7…
Phase 4 N=33 Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS
Multiple Sclerosis · Autonomic Nervous System Dysfunction
Primary: RMSSD Normal Breathing — 14.10 milliseconds — p=0.02
Phase 1 N=18 Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine
Healthy Volunteers
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) of Caffeine After a Dose of PBT2 250mg — 32775 ng*hr/mL
Phase 4 N=48 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Exudative Age-related Macular Degeneration · Polypoidal Choroidal Vasculopathy
Primary: Percentage of Patients Lose Visual Acuity Less Than 15 Letters — 87.5 percentage of patients
N/A N=30 BIOCLEAN FIRST CARE EX in Combination With Biofinity Lens
Myopia
Primary: Ocular Health - Corneal Staining — 38; 35; 18; 20 Eyes
Phase 1 N=103 A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)
Hypertension · Isolated Systolic Hypertension
Primary: Number of Participants With an Adverse Event (AE) — 4; 5; 6; 3 participants
Phase 3 N=485 Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis
Bronchiectasis
Primary: Rate of Graded Pulmonary Exacerbations — 1.95; 2.10; 1.69; 1.84 GPE events per year — p=0.3115
N/A N=104 Physical Therapy Versus Steroid Injection for Shoulder Impingement Syndrome
Shoulder Impingement Syndrome
Primary: Shoulder Pain and Disability Index — 21.6; 23.1 units on a scale
Phase 1 N=36 Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Febuxostat — 883.58; 1075.08; 765.89; 1456.42 nanogram per milliliter (ng/mL)
Phase 3 N=821 Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Primary: Overall Survival (OS) at Primary Endpoint — 25.00; 19.55 months — p=0.0018
Phase 3 N=617 Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis
Allergic Rhinitis
Primary: The Change From Baseline in Rhinoconjunctivitis Symptoms Score at 11 - 12 Months Between the Actively Treated Patients and the Placebo Treated. — -1.77; -1.83 units on a…